

## References

1. Polman CH, Uitdehaag BM. Drug treatment of multiple sclerosis. *West J Med.* 2000;173:398-402.
2. Weinschenker BG, Bass B, Rice GP, et al. The natural history of multiple sclerosis: a geographically based study. I. Clinical course and disability. *Brain.* 1989;112:133-146.
3. Lublin FD, Reingold SC. Defining the clinical course of multiple sclerosis: results of an international survey. National Multiple Sclerosis Society (USA) Advisory Committee on Clinical Trials of New Agents in Multiple Sclerosis. *Neurology.* 1996;46:907-911.
4. Jacobs LD, Cookfair DL, Rudick RA, et al. Intramuscular interferon beta-1a for disease progression in relapsing multiple sclerosis. The Multiple Sclerosis Collaborative Research Group (MSCRG). *Ann Neurol.* 1996;39:285-294.
5. IFNB Multiple Sclerosis Study Group. Clinical results of a multicenter, randomized, double-blind, placebo-controlled trial. *Neurology.* 1993;43:655-661.
6. IFNB Multiple Sclerosis Study Group. Interferon beta-1b in the treatment of multiple sclerosis: final outcome of the randomized controlled trial. *Neurology.* 1995;45:1277-1285.
7. Johnson KP, Brooks BR, Cohen JA, et al. Copolymer 1 reduces relapse rate and improves disability in relapsing-remitting multiple sclerosis: results of a phase III multicenter, double-blind placebo-controlled trial. The Copolymer 1 Multiple Sclerosis Study Group. *Neurology.* 1995;45:1268-1276.
8. PRISMS (Prevention of Relapses and Disability by Interferon beta-1a Subcutaneously in Multiple Sclerosis) Study Group. Randomised double-blind placebo-controlled study of interferon beta-1a in relapsing/remitting multiple sclerosis. *Lancet.* 1998;352:1498-1504.
9. Polman CH, O'Connor PW, Havrdova E, et al. A randomized, placebo-controlled trial of natalizumab for relapsing multiple sclerosis. *N Engl J Med.* 2006;354:899-910.
10. Stüve O, Bennett JL. Pharmacological properties, toxicology and scientific rationale for the use of natalizumab (Tysabri) in inflammatory diseases. *CNS Drug Rev.* 2007;13:79-95.
11. Rudick RA, Stuart WH, Calabresi PA, et al. Natalizumab plus interferon beta-1a for relapsing multiple sclerosis. *N Engl J Med.* 2006;354:911-923.
12. Zivadinov R, Rudick RA, De Masi R, et al. Effects of IV methylprednisolone on brain atrophy in relapsing-remitting MS. *Neurology.* 2001;57:1239-1247.

13. National Clinical Advisory Board of the National Multiple Sclerosis Society. Recommendations regarding corticosteroids in the management of multiple sclerosis. Expert Opinion Paper. Available at: <http://www.nationalmssociety.org/for-professionals/healthcare-professionals/publications/expert-opinion-papers/index.aspx>. Accessed November 6, 2008.
14. Weinschenker BG. Plasma exchange for severe attacks of inflammatory demyelinating diseases of the central nervous system. *J Clin Apher.* 2001;16:39-42.
15. Lassmann H, Brück W, Lucchinetti C. Heterogeneity of multiple sclerosis pathogenesis: implications for diagnosis and therapy. *Trends Mol Med.* 2001;7:115-121.
16. Keegan M, König F, McClelland R, et al. Relation between humoral pathological changes in multiple sclerosis and response to therapeutic plasma exchange. *Lancet.* 2005;366:579-582.
17. Edan G, Miller D, Clanet M, et al. Therapeutic effect of mitoxantrone combined with methylprednisolone in multiple sclerosis: a randomised multicentre study of active disease using MRI and clinical criteria. *J Neurol Neurosurg Psychiatry.* 1997;62:112-118.
18. van de Wyngaert FA, Beguin C, D'Hooghe MB, et al. A double-blind clinical trial of mitoxantrone versus methylprednisolone in relapsing, secondary progressive multiple sclerosis. *Acta Neurol Belg.* 2001;101:210-216.
19. Mitoxantrone for injection concentrate [prescribing information]. Rockland, MA: Serono, Inc; 2008.
20. Frohman EM, Brannon K, Racke MK, Hawker K. Mycophenolate mofetil in multiple sclerosis. *Clin Neuropharmacol.* 2004;27:80-83.
21. Sylvester S. Combination mycophenolate mofetil (CellCept) and interferon beta (rebif/betaferon) safe and effective in advanced MS. Presented at: 21st Congress of the European Committee for Treatment and Research in Multiple Sclerosis; September 28-October 1, 2005; Thessaloniki, Greece. Available at: <http://www.docguide.com/news/content.nsf/news/8525697700573E1885257092006E794F>. Accessed November 7, 2008.
22. Hirst CL, Pace A, Pickersgill TP, et al. Campath 1-H treatment in patients with aggressive relapsing remitting multiple sclerosis. *J Neurol.* 2008;255:231-238.
23. Alemtuzumab [prescribing information]. Wayne, NJ: Bayer HealthCare Pharmaceuticals Inc; 2007.

24. Medical News Today. Genzyme and Bayer HealthCare announce detailed interim two-year alemtuzumab in multiple sclerosis data presented at AAN. Available at: <http://www.medicalnewstoday.com/articles/69669.php>. Accessed December 1, 2008.
25. Cross AH, Stark JL, Lauber J, Ramsbottom MJ, Lyons JA. Rituximab reduces B cells and T cells in cerebrospinal fluid of multiple sclerosis patients. *J Neuroimmunol*. 2006;180:63-70.
26. Hauser SL, Waubant E, Arnold DL, et al. B-cell depletion with rituximab in relapsing-remitting multiple sclerosis. *N Engl J Med*. 2008;358:676-688.
27. US Food and Drug Administration. Rituximab. FDA Alert. Available at: <http://www.fda.gov/CDER/Drug/InfoSheets/HCP/rituximab.pdf>. Accessed November 7, 2008.
28. Smith DR, Weinstock-Guttman B, Cohen JA, et al. A randomized blinded trial of combination therapy with cyclophosphamide in patients with active multiple sclerosis on interferon beta. *Mult Scler*. 2005;11:573-582.
29. Gladstone DE, Zamkoff KW, Krupp L, et al. High-dose cyclophosphamide for moderate to severe refractory multiple sclerosis. *Arch Neurol*. 2006;63:1388-1393.
30. Krishnan C, Kaplin AI, Brodsky RA, et al. Reduction of disease activity and disability with high-dose cyclophosphamide in patients with aggressive multiple sclerosis. *Arch Neurol*. 2008;65:1044-1051.